New Malaria drug from Novartis could tackle growing drug resistance
Novartis, a Switzerland-based pharmaceutical company, has developed a new anti-malaria drug called GanLum, which has been found to be highly effective against the mosquito-borne disease. Involving 1,688 adults and children across 34 sites in 12 African countries, the phase III trial found GanLum cured more than 97% of patients.